Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc. (NASDAQ: GALT) generates frequent news as a clinical-stage biopharmaceutical company developing galectin-targeted therapies for chronic liver disease and cancer. Most company updates focus on belapectin, its carbohydrate-based galectin-3 inhibitor, and the lead program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension.
On this page, readers can follow news about clinical data from the NAVIGATE trial and related analyses, including outcomes on liver stiffness by FibroScan, Enhanced Liver Fibrosis (ELF) scores, and serum biomarkers such as PRO-C3, YKL-40, and PRO-C4. Galectin Therapeutics often reports how these measures relate to the incidence of new esophageal varices and portal hypertension risk categories in patients with compensated MASH cirrhosis.
News items also cover regulatory interactions with the U.S. Food and Drug Administration, such as Type C meeting requests, written feedback on trial design, and plans for potential pivotal Phase 3 development of belapectin. Investors can find announcements about Fast Track designation, presentation of NAVIGATE data at major liver disease meetings like AASLD and EASL, and participation in investor conferences and virtual key opinion leader events.
In addition, Galectin Therapeutics issues press releases on quarterly financial results, new or extended lines of credit and convertible notes, and corporate governance matters. These updates provide context on the company’s capital resources, development priorities, and timing of planned activities. For anyone tracking GALT, this news feed offers a centralized view of clinical milestones, regulatory developments, financing arrangements, and strategic communications related to belapectin and the company’s broader galectin-targeted pipeline.
Galectin Therapeutics (GALT) announced promising results from a Phase 1 study combining belapectin, a galectin-3 inhibitor, with pembrolizumab (KEYTRUDA®) for treating advanced melanoma and head and neck cancers. In this study, 50% of melanoma and 33% of HNSCC patients showed an objective response, outperforming pembrolizumab alone. The combination therapy exhibited fewer adverse events and improved tumor microenvironment conditions. A randomized Phase 2 trial is planned to further evaluate efficacy and safety, building on these positive findings.
Galectin Therapeutics is currently recruiting patients for the NAVIGATE study, a Phase 2b/3 clinical trial investigating belapectin for preventing esophageal varices in patients with NASH cirrhosis. As the only treatment option is liver transplant, this trial represents a significant opportunity for patients. The study aims to enroll around 315 participants across 130 sites worldwide. Belapectin has shown potential in earlier studies to prevent esophageal varices, a serious complication of cirrhosis.
Galectin Therapeutics Inc. (NASDAQ: GALT) reported a fiscal 2020 net loss of $23.6 million, or $0.41 per share, up from a loss of $20.2 million in 2019. The increase in losses was primarily due to higher research and development costs, particularly for the NAVIGATE clinical trial. The Company has $27.1 million in cash and expects additional funding needs of approximately $45-$50 million to advance the NAVIGATE trial through its upcoming interim analysis in late 2023. CEO Joel Lewis expressed optimism about ongoing studies and organizational improvements.
Galectin Therapeutics (NASDAQ:GALT) announced significant findings published in OncoImmunology regarding belapectin, a galectin-3 inhibitor. Research showed that belapectin combined with an anti-OX40 antibody effectively reduces tumor progression, enhancing survival in tumor-bearing mice. This validates ongoing clinical trials combining belapectin with pembrolizumab (Keytruda), indicating potential to improve cancer treatment. Additionally, belapectin is under investigation for treating NASH cirrhosis, highlighting its dual focus on oncology and liver diseases.
Galectin Therapeutics (NASDAQ:GALT) announced that Dr. Pol Boudes, M.D., the Chief Medical Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be accessible on-demand from March 9 at 7:00 am (EST) and will be archived for 90 days. The company focuses on developing therapies for chronic liver disease and cancer, with its lead drug, belapectin, targeting galectin-3, significant in inflammatory and malignant diseases, and holds FDA Fast Track designation.
Galectin Therapeutics (NASDAQ:GALT) announced that Dr. Pol F. Boudes, Chief Medical Officer, will present on Belapectin, a galectin-3 inhibitor in Phase 2b/3 for treating NASH cirrhosis, at the 4th Annual Digital NASH Summit on December 17, 2020, at 09:00 AM EST.
Belapectin targets galectin-3, a protein linked to liver diseases. Preclinical studies indicate its potential to reverse liver fibrosis and cirrhosis, with encouraging results from the NASH-CX clinical trial.
Galectin Therapeutics (NASDAQ:GALT) announced a successful 2020 Annual Meeting, where management updates highlighted clinical trials for belapectin, targeting cirrhosis. The transition in management was seamless, according to Chairman Dick Uihlein. CEO Joel Lewis emphasized the importance of data from a pharmacokinetic study for future research. Chief Medical Officer Pol Boudes discussed a promising combination therapy trial with Keytruda. The company aims to address non-alcoholic steatohepatitis (NASH), a significant liver condition affecting millions.
Galectin Therapeutics Inc. (NASDAQ:GALT) will present a corporate update during its 2020 Annual Meeting of Stockholders on December 3, 2020, at 11:00 a.m. EST. This live webcast follows the business portion of the meeting and can be accessed online. The company focuses on developing therapies for chronic liver disease and cancer, with its lead drug, belapectin, targeting galectin-3 protein involved in various inflammatory and malignant diseases. Belapectin has received Fast Track designation for NASH cirrhosis by the FDA. Additional programs are underway in immunotherapy for advanced melanoma.
Galectin Therapeutics (NASDAQ: GALT) initiated its Phase 2b/3 NASH-RX trial targeting NASH cirrhosis, aiming to address a critical medical need. CEO Joel Lewis highlighted the trial's unique position as one of the few late-stage studies in this field. The first patient was enrolled in August 2020, with plans for global patient inclusion. Key appointments to the board, including Richard Zordani and Dr. Elissa Schwartz, aim to enhance financial and clinical expertise. The company also continues its commitment to the development of belapectin, a galectin-3 inhibitor, with potential applications beyond NASH cirrhosis.
Galectin Therapeutics (NASDAQ:GALT) announced an investor conference call to discuss its NASH-RX clinical trial and introduce new CEO Joel Lewis. The event is set for September 29, 2020, at 4:00 p.m. EDT, accessible via a dedicated phone line or webcast. The company aims to develop therapies for chronic liver disease and cancer, with its lead drug belapectin showing promise in treating NASH with cirrhosis. The press release also included forward-looking statements regarding the potential success of ongoing clinical programs and the challenges ahead.